
Therapeutic Area
Indication
Ulcerative Colitis
1
PRECLINICAL
Preclinical
PHASE I
PHASE IIA
PHASE IIB
PHASE III
MARKET
T cells play a key role in immune system, and are particularly important in the chain of events that are believed to lead to the inflammation and autoimmunity.
Based on current structure of ALTB-168, a second generation of the therapeutic antibody with multivalent design that leads to improve potency is being under development. So far, in vitro and in vivo studies with this modified antibody have demonstrated a 10-fold increase at least in activity of abolishing activated T cells (killer immune cells that cause inflammation). The company is dedicated to bring forth this potential candidate for pre-clinical studies.
Solid Organ Transplantation
2
PRECLINICAL
Preclinical
PHASE I
PHASE IIA
PHASE IIB
PHASE III
MARKET
Solid organ transplantation is a potentially life-saving option for patients faced with terminal organ failure. However, immunosuppressive drugs are needed for prevention of rejection of transplanted organs and long-term administration of immunosuppressive medications has potential unfavorable consequences including increased susceptibility to opportunistic infections and malignancies.
Because of the unique MOA of ALTB-168, we believe it has the potential for a durable response allowing patients to avoid long-term administration of immunosuppressive medications. We are currently studying the use of ALTB-168 in preclinical non-human primate renal transplantation models.